![[Podcast] Trial Trailblazers: Behind clinical breakthroughs](https://imgproxy.divecdn.com/cr_gUY8HHfHKWVfM5mEkCyXB9OzVqKd0L_Zq5ZJQSoM/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlX1BvZGNhc3RfY292ZXIxMzQ2eDcyOV9SMi5wbmc=.webp)
Metsera posts weight loss data for amylin analog, teeing up monthly GLP-1 combo plans
Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ultralong-acting challenger to candidates in development at AbbVie, Eli Lilly, Novo Nordisk and Roche.
Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ultralong-acting challenger to candidates in development at AbbVie, Eli Lilly, Novo Nordisk and Roche.
